Ozempic lawsuit claims have surged across the country as thousands of patients report severe gastrointestinal injuries. These lawsuits allege that manufacturers of GLP-1 receptor agonist drugs failed to warn about risks of stomach paralysis. The litigation has been consolidated into a federal multidistrict litigation in Pennsylvania. As of May 2026, approximately 3,636 cases are pending in MDL-3094. If you used Ozempic, Wegovy, Mounjaro, or similar drugs and suffered serious digestive injuries, you may qualify to file a claim.
Case Timeline
Last checked: July 10, 2026
Advertisement
July 10, 2026 (Case Status): MDL 3094 (E.D. Pa.) now has 3,848 pending lawsuits as of July 1, 2026, up from 3,763 in June. (Court Record)
July 10, 2026 (Bellwether Date): No bellwether trial date has been set yet; first bellwether trials are now expected in late 2026 or early 2027. (Court Record)
July 10, 2026 (Ruling): The MDL is presided over by Judge Karen S. Marston (not Gene E.K. Pratter, who is deceased), and as of Feb 2026 the court now requires high-level diagnostic proof (e.g., gastric-emptying scintigraphy) rather than general failure-to-warn allegations. (Court Record)
July 10, 2026 (Settlement): As of July 2026 there is no global settlement in either the GI-injury MDL 3094 or the NAION vision-loss MDL 3163, with resolution likely years away. (Court Record)
July 10, 2026 (Other): A status conference was held June 23, 2026, with parties preparing for upcoming expert-witness (Daubert) and summary-judgment proceedings. (Court Record)
July 09, 2026: People Are Experiencing Such Bad Ozempic Side Effects That It Might Result In $2B In Lawsuits – AOL.com (AOL.com)
July 09, 2026: Ozempic Face, Blindness Claims, And Billions In Potential Damages: The GLP-1 Reckoning – Dallas Express (Dallas Express)
July 03, 2026 (Case Status): Presiding judge is now Karen S. Marston (E.D. Pa.); Judge Gene E.K. Pratter is deceased (2024) and no longer oversees MDL-3094. (Court Record)
July 03, 2026 (Case Status): As of June 1, 2026, 3,848 gastroparesis/GI lawsuits are pending in MDL-3094, plus 146 in the separate GLP-1 vision-loss (NAION) MDL-3163. (Court Record)
July 03, 2026 (Bellwether Date): No bellwether trial date has been set as of mid-2026; first bellwether trials are now projected for late 2026 or early 2027. (Court Record)
July 03, 2026 (Ruling): Case Management Order No. 30 (entered January 2026) is advancing the litigation toward expert disclosures and Daubert briefing. (Court Record)
July 03, 2026 (Ruling): Judge Marston’s August 2025 order allowed 12 of 17 counts against Novo Nordisk and Eli Lilly to survive dismissal, keeping the core failure-to-warn claims alive. (Court Record)
July 03, 2026 (Settlement): No global settlement framework exists and settlement talks have not begun as of mid-2026; no settlement timeline has been announced. (Court Record)
July 01, 2026: Parker Waichman LLP Files Lawsuits on behalf of Georgia and California Residents Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic – PR Newswire (PR Newswire)
July 01, 2026: Saxenda Lawsuit | NAION Liraglutide Risks (2026) – Sokolove Law (Sokolove Law)
June 29, 2026: Health Care Inc: Private ERs, CA hospital lawsuits, GLP-1s, pizza – statnews.com (statnews.com)
June 11, 2026: Research Links Ozempic to Vision Loss as GLP-1 Lawsuits Increase – The Legal Examiner (The Legal Examiner)
June 26, 2026 (Case Status): MDL-3094 is now overseen by Judge Karen S. Marston (E.D. Pa.), not Judge Gene E.K. Pratter, who is no longer presiding. (Court Record)
June 26, 2026 (Case Status): As of early February 2026 the consolidated MDL grew to roughly 3,191–3,600+ pending gastroparesis actions, with expert discovery scheduled to close around March 2026. (Court Record)
June 26, 2026 (Case Status): NAION/vision-loss claims were split off into a separate MDL 3163 (also before Judge Marston), with ~86 blindness lawsuits pending as of May 2026. (Court Record)
June 26, 2026 (Bellwether Date): No formal bellwether trial date has been set; bellwether trials are expected in late 2026 or early 2027. (Court Record)
June 26, 2026 (Settlement): No global settlement framework or class settlement is in place as of mid-2026; analysts estimate total manufacturer liability could exceed $2 billion. (Court Record)
June 25, 2026: Parker Waichman LLP Files Lawsuit on behalf of Ohio Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic – PR Newswire (PR Newswire)
June 22, 2026: South Africa court bars iDexis from selling compounded Ozempic in Novo Nordisk case – Reuters (Reuters)
June 22, 2026: Ozempic Ruined Their Lives | Here’s What They’re Claiming | Ozempic Lawsuit Marco Silva (Ua6AJ2Gu32) – Mshale (Mshale)
June 11, 2026: Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases – Reuters (Reuters)
June 16, 2026: Wegovy Vision Side Effects Resulted in Blindness in Left Eye, Lawsuit Alleges – AboutLawsuits.com (AboutLawsuits.com)
June 12, 2026 (Ruling): Judge Karen Marston issued a major ruling on gastroparesis diagnosis requirements after 3,700+ pages of briefing, now requiring high-level diagnostic proof (e.g., scintigraphy) to separate drug-induced injuries from pre-existing conditions. (Court Record)
June 12, 2026 (Case Status): MDL-3094 has grown to 3,636+ pending gastroparesis cases as of May 2026, plus 86 NAION vision-loss cases in the separate MDL-3163, both before Judge Marston in E.D. Pa. (Court Record)
June 12, 2026 (Other): A new MDL-3163 was created specifically for NAION (vision loss) claims with 29 actions, splitting off from the gastroparesis-focused MDL-3094. (Court Record)
June 12, 2026 (Bellwether Date): No bellwether trial dates have been formally set; trials are expected late 2026 or early 2027. (Court Record)
June 12, 2026 (Other): Science Day was scheduled for June 2, 2026 in the NAION litigation; discovery is ongoing with expert witness reports expected mid-2026. (Court Record)
June 12, 2026 (Settlement): No settlement talks have begun as of May 2026; legal analysts project total manufacturer liability could exceed $2 billion across all GLP-1 claims. (Court Record)
June 11, 2026: Research Links GLP-1s to Vision Loss as Lawsuits Increase – The Legal Examiner (The Legal Examiner)
June 11, 2026: Novo Advances Lawsuit Against Pharmacy’s Ozempic, Wegovy Copies – Bloomberg Law News (Bloomberg Law News)
June 10, 2026: User Says ‘Nature’s Ozempic’ Can’t Keep Weight Loss Promise – Law360 (Law360)
June 09, 2026: Parker Waichman LLP Files Lawsuit on behalf of Massachusetts Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy – PR Newswire (PR Newswire)
June 08, 2026: Lawyer, doctor speak on lawsuit accusing GLP-1 drugs causing severe side effects | NewsNation Prime – Queen City News (Queen City News)
June 08, 2026: Lawyer, doctor speak on lawsuit accusing GLP-1 drugs causing severe side effects | NewsNation Prime – KARK (KARK)
June 08, 2026: Lawyer, doctor speak on lawsuit accusing GLP-1 drugs causing severe side effects | NewsNation Prime – NEWS10 ABC (NEWS10 ABC)
June 05, 2026 (Case Status): MDL-3094 has grown to 3,636+ pending gastroparesis cases and 86 NAION vision-loss cases (MDL-3163) as of May 2026, both overseen by Judge Karen S. Marston in E.D. Pa. (Court Record)
June 05, 2026 (Ruling): Judge Marston issued a major ruling on gastroparesis diagnosis requirements after reviewing 3,700+ pages of briefing and evidentiary hearings. (Court Record)
June 05, 2026 (Other): A Science Day was scheduled for June 2, 2026, where the court evaluates the scientific evidence underlying plaintiffs’ claims. (Court Record)
June 05, 2026 (Bellwether Date): Bellwether trials are expected in late 2026 through 2027; specific trial dates have not yet been formally set and bellwether case selection is still pending. (Court Record)
June 05, 2026 (Settlement): No class action settlement has been reached; mass settlements are considered unlikely before late 2027, with bellwether outcomes expected to shape compensation values. (Court Record)
June 05, 2026 (Case Status): A separate MDL-3163 was created specifically for NAION vision-loss claims (29 actions pending), splitting eye-injury cases from the gastroparesis track in MDL-3094. (Court Record)
June 05, 2026 (Other): Note: Presiding judge is Karen S. Marston, not Gene E.K. Pratter — Pratter was originally assigned but Marston now oversees both MDL-3094 and MDL-3163. (Court Record)
June 01, 2026: People are overdosing on GLP-1 injections. What does that look like? – Straight Arrow News – SAN (Straight Arrow News – SAN)
June 01, 2026: Parker Waichman LLP Files Lawsuit on behalf of Pennsylvania Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy – PR Newswire (PR Newswire)
May 28, 2026: CVS Caremark to cover Zepbound again after lawsuit, widespread backlash – LiveNOW from FOX (LiveNOW from FOX)
May 28, 2026: CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo – Fierce Pharma (Fierce Pharma)
April 14, 2026: Lawsuit claims GLP-1 diet drug killed Texas woman – KING5.com (KING5.com)
May 04, 2026: Ozempic Vision Loss Lawsuit Highlights Devastating Consequences of NAION Diagnosis – AboutLawsuits.com (AboutLawsuits.com)
May 22, 2026: Parker Waichman LLP Files Lawsuit on behalf of Florida Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic – PR Newswire (PR Newswire)
May 19, 2026: Ozempic Lawsuit 2026: Stomach Paralysis, Vision Loss & Legal Options – Consumer Notice (Consumer Notice)
May 22, 2026 (Case Status): MDL-3094 case count has grown to over 3,600 gastroparesis lawsuits pending in federal court as of May 2026, up from 2,947 in December 2025. (Court Record)
May 22, 2026 (Other): A separate MDL-3163 was created in December 2025 in E.D. Pa. to centralize GLP-1 vision loss (NAION) claims, now with 86 blindness lawsuits pending. (Court Record)
May 22, 2026 (Other): Judge Karen S. Marston is now referenced as presiding judge over both MDLs in E.D. Pa., alongside Judge Pratter. (Court Record)
May 22, 2026 (Ruling): Expert discovery in MDL-3094 closed around March 2026; expert witness reports are due mid-2026. (Court Record)
May 22, 2026 (Other): A Science Day has been scheduled for June 2, 2026 in the NAION MDL-3163 litigation. (Court Record)
May 22, 2026 (Settlement): No global settlement has been reached in either MDL; formal settlement talks have not begun and mass settlements are unlikely before late 2027. (Court Record)
May 21, 2026: Mounjaro NAION Lawsuit Claims Side Effects Led to Permanent Vision Loss – AboutLawsuits.com (AboutLawsuits.com)
December 15, 2025: Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs – Reuters (Reuters)
January 30, 2026: Ozempic Lawsuits Over Vision Loss, Stomach Problems on the Rise – Drugwatch.com (Drugwatch.com)
May 18, 2026: Ozempic (Semaglutide): Side Effects, Risks & FDA Warnings – Drugwatch.com (Drugwatch.com)
May 11, 2026: Weight Loss Drug Lawsuits | Learn More About GLP-1 Lawsuits – Motley Rice (Motley Rice)
May 03, 2026: Wegovy Lawsuit 2025-26 | Gastroparesis & Wegovy Settlements – Sokolove Law (Sokolove Law)
May 14, 2026: Wegovy Side Effects: Common & Serious Risks – Motley Rice (Motley Rice)
April 30, 2026: Eli Lilly’s GLP-1 lawsuit against Houston’s Empower Pharmacy partially dismissed – Houston Chronicle (Houston Chronicle)
May 15, 2026: Judge dismisses part of Eli Lilly’s GLP-1 lawsuit against Houston’s Empower Pharmacy – MSN (MSN)
May 11, 2026: DOJ sues OhioHealth over alleged anticompetitive hospital contracts; Novo to slash Ozempic, Wegovy prices up to 50% in 2027; lightweight ‘exoskeleton’ helps stroke survivors walk – Morning Medical Update – Medical Economics (Medical Economics)
May 15, 2026 (Case Status): MDL-3094 case count has grown to 3,636 pending actions as of May 1, 2026; a separate NAION/vision-loss MDL (No. 3163) now has 86 cases. (Court Record)
May 15, 2026 (Other): Presiding judge is now Karen S. Marston (E.D. Pa.), not Gene E.K. Pratter — verify whether reassignment occurred. (Court Record)
May 15, 2026 (Bellwether Date): No bellwether trials have been scheduled yet; bellwether case selection is expected later in 2026, with trials likely extending into 2027. (Court Record)
May 15, 2026 (Ruling): Judge Marston scheduled a Science Day for June 2, 2026 in the NAION/vision-loss MDL (MDL-3163), giving each side 2.5 hours to present non-adversarial scientific evidence. (Court Record)
May 15, 2026 (Settlement): No global settlement has been announced in either MDL; legal analysts project mass settlements are unlikely before late 2027, with projected individual values of $100K–$2M+ depending on injury severity. (Court Record)
May 15, 2026 (Other): FDA warning activity continues around GLP-1 drugs; 75% of MDL-3094 complaints cite gastroparesis, 18% cite ileus, 8% cite gallbladder complications. (Court Record)
What Is the Ozempic Lawsuit About?
| MDL Detail |
Current Data |
| MDL Number |
MDL-3094 |
| Pending Cases |
1 |
| Presiding Judge |
Gene E.K. Pratter |
| Federal District |
E.D. Pa. |
| Data Source |
U.S. Judicial Panel on Multidistrict Litigation |
| Last Updated |
July 06, 2026 |
The Ozempic lawsuit centers on GLP-1 receptor agonist medications prescribed for type 2 diabetes and weight loss. These drugs include semaglutide products like Ozempic, Wegovy, and Rybelsus made by Novo Nordisk. They also include tirzepatide products like Mounjaro and Zepbound made by Eli Lilly. Plaintiffs allege the manufacturers knew about serious gastrointestinal risks but failed to adequately warn patients and doctors.
The primary injury alleged is gastroparesis, also called stomach paralysis. This condition causes the stomach to empty food abnormally slowly. Roughly 75 percent of cases in the MDL involve gastroparesis claims. Other injuries include ileus, which is intestinal blockage, accounting for about 18 percent of claims. Gallbladder injuries make up approximately 8 percent. Many plaintiffs report chronic nausea, vomiting, and severe abdominal pain lasting months or years.
In September 2023, the FDA updated the Ozempic label to include a warning about ileus. Then in January 2025, the label was revised again. It now states that Ozempic is “not recommended in patients with severe gastroparesis.” However, plaintiffs argue these warnings came too late. They contend the manufacturers had earlier evidence of these risks and chose not to disclose them promptly.
MDL Case Status and Key Facts
| Detail |
Information |
| MDL Number |
3094 |
| Full Title |
In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation |
| Presiding Judge |
Hon. Karen Spencer Marston |
| Federal District |
Eastern District of Pennsylvania |
| Approximate Case Count |
3,636 (as of May 2026) |
| Consolidated |
September 2023 |
| Key Defendants |
Novo Nordisk, Eli Lilly |
| Bellwether Trials |
Expected late 2026 or early 2027 |
The Judicial Panel on Multidistrict Litigation consolidated these cases in September 2023. Judge Marston oversees all pretrial proceedings in Philadelphia. Fact discovery closed in late 2025. Expert reports from both sides were filed in early 2026. As a result, the litigation is now entering the critical Daubert motion phase.
On August 15, 2025, Judge Marston issued a significant causation ruling. The order requires any plaintiff claiming gastroparesis to show a diagnosis based on a properly performed gastric emptying study. This raised the evidentiary bar considerably. Bellwether trial selection is expected by mid-2026. A separate MDL, number 3163, handles vision loss claims related to these same drugs.
Who Qualifies for the Ozempic Lawsuit?
You might be eligible for the Ozempic lawsuit if you meet several criteria. First, you must have taken a GLP-1 receptor agonist medication. This includes Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or Trulicity. Second, you must have developed a qualifying injury after starting the medication. Typically, the most common qualifying conditions are gastroparesis, ileus, and gallbladder disease.
Medical documentation is essential for any Ozempic lawsuit claim. For example, gastroparesis claims require a confirmed diagnosis through a gastric emptying scintigraphy study. You will also need records showing when you started and stopped the medication. Hospital records, emergency room visits, and surgical reports strengthen your case. In most cases, a clear timeline connecting drug use to injury onset is critical.
There is no single cutoff date for when the drug was used. However, the strength of your claim depends on several factors. These include the severity of your injury, duration of drug use, and your medical history. A licensed attorney can evaluate whether your specific situation qualifies. Many firms handling Ozempic lawsuit cases offer free initial consultations.
How to File an Ozempic Lawsuit Claim
The first step in filing an Ozempic lawsuit is consulting a qualified mass tort attorney. Look for firms with experience in pharmaceutical litigation. Many attorneys work on a contingency basis. This means you pay nothing upfront. They only collect fees if you receive compensation. An attorney can review your medical records and determine claim viability.
After retaining counsel, your attorney will file a complaint. If filed in federal court, your case will typically be transferred to MDL-3094 in Pennsylvania. You will need to complete a Plaintiff Fact Sheet. This detailed questionnaire covers your medical history, drug usage, and injuries. Accurate and thorough responses are important. Additionally, your attorney may need to obtain your pharmacy records and medical imaging results.
Statute of limitations deadlines vary by state. In most cases, you have two to three years from when you discovered the injury. Some states apply a “discovery rule.” This means the clock starts when you became aware of the connection between the drug and your condition. However, waiting too long can jeopardize your claim. Consulting an attorney promptly is strongly recommended.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Settlement Updates and What to Expect
As of May 2026, no global settlement has been reached in the Ozempic lawsuit. The litigation remains in pretrial stages. Bellwether trials have not yet occurred. These initial trial cases are typically selected to test the strength of both sides’ arguments. Their outcomes heavily influence future settlement negotiations. Legal analysts project a resolution window of 2026 through 2029.
Settlement amounts in pharmaceutical MDLs vary widely based on injury severity. Factors that affect potential compensation include the type of injury, duration of suffering, and medical costs incurred. Surgical interventions like gallbladder removal may increase claim value. However, no specific payout amounts are guaranteed. Each Ozempic lawsuit claim is evaluated individually based on its facts.
The August 2025 causation ruling could significantly affect outcomes. Cases with strong diagnostic evidence may fare better. Conversely, claims lacking proper gastric emptying studies may face challenges. The Daubert hearing results, expected in mid-2026, will determine which expert testimony is admissible at trial. These rulings will shape the trajectory of the entire Ozempic lawsuit litigation.
State-by-State Considerations
While most Ozempic lawsuit cases are consolidated in the federal MDL, state laws still matter. Each plaintiff’s claim is governed by their home state’s tort laws. For example, states like Texas and Florida have enacted tort reform measures that may cap damages. Meanwhile, states such as Pennsylvania, New Jersey, and California tend to be more plaintiff-friendly. New Jersey also hosts parallel multicounty litigation alongside the federal MDL.
Statute of limitations periods differ by state and can range from one to six years. Some states have stricter rules about expert testimony requirements. Others have different standards for proving causation. As a result, where you live can meaningfully affect your case. You can learn more about how your state’s laws apply on our state-by-state tort reform guide. Consulting a licensed attorney familiar with your state’s rules is essential.
Frequently Asked Questions
Is the Ozempic lawsuit still accepting new cases?
Yes, new Ozempic lawsuit cases continue to be filed and added to MDL-3094. No filing deadline has been set by the court for joining the MDL. However, your individual statute of limitations still applies. Contact a mass tort attorney as soon as possible to protect your rights.
Can I still take Ozempic if I file a lawsuit?
Filing an Ozempic lawsuit does not require you to stop taking the medication. That is a medical decision between you and your doctor. However, your continued use of the drug may be relevant to your case. Your attorney can advise you on how this might affect your claim.
How long will the Ozempic lawsuit take to resolve?
Pharmaceutical MDL cases typically take three to six years from consolidation to resolution. MDL-3094 was consolidated in September 2023. Bellwether trials are expected to begin in late 2026 or early 2027. Settlement negotiations often follow bellwether outcomes. In most cases, plaintiffs should expect a timeline extending into 2027 or beyond.
Check If You May Qualify
Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.
Official Sources & Resources
For verified mass tort and MDL information:
- JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
- DOJ: justice.gov — settlement announcements and press releases
- FDA: fda.gov — drug recalls, warning letters, and safety alerts
- CDC: cdc.gov — health condition data and exposure guidelines
- EPA: epa.gov — environmental contamination data
- Cornell LII: law.cornell.edu — plain-English legal definitions
Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.
Related Guides
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.
